Can BridgeBio Pharma (BBIO) Stock Reach $110?

Key Takeaways

• The central target of $110 is the rounded arithmetic mean of roughly 10 verified, current individual analyst price targets, which span from about $91 to $156.
• At a recent close near $67.55, reaching $110 would require a gain of roughly 63% — a very large move.
• The published analyst consensus leans clearly bullish, with most firms rating the stock Buy or Overweight and a consensus near $105–$111 across major aggregators.
• The strongest support comes from the fast-growing launch of the heart drug Attruby, while the biggest risks are commercial execution, an unprofitable bottom line, and valuation.
• Key catalysts ahead include third-quarter earnings and two pending U.S. Food and Drug Administration (FDA) decisions on pipeline programs.

Analyst Price Targets and Consensus View

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biotechnology company developing treatments for genetic diseases. The $110 central target is a calculated average of identifiable, current analyst targets — not an official published consensus. Individual targets used include Barclays at $156, Piper Sandler at $120, H.C. Wainwright at $120, Jefferies at $110, Wells Fargo, BofA, and Truist at $102, RBC Capital at $100, UBS at $92, and Citi at $91. The range is wide, from roughly $91 to $156, reflecting genuine disagreement about how much of the Attruby opportunity is already reflected in the share price.

Aggregators report a similar picture: S&P Global data shows an average target near $108 with a "Strong Buy" consensus, while MarketBeat and TipRanks point to roughly $105–$111. Recent revisions have been mixed. In October 2026, Piper Sandler raised its target to $120 from $115, while BofA trimmed to $102 from $104 and Citi lowered to $91 from $94. The divergence is largely about how aggressively each firm models Attruby's commercial ramp and pipeline optionality.

Current Market Position and Path Toward the Target

BBIO shares closed near $67.55 on October 20, 2026, within a 52-week range of $52.75 to $93.42 and a market capitalization of about $13.2 billion. Reaching $110 implies a gain of roughly 63% — a very large move that would require the stock to break decisively above its prior 52-week high and re-rate higher on sustained commercial momentum rather than a single catalyst.

The path runs through the launch of Attruby (acoramidis), approved in late 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive form of heart failure. In the first quarter of 2026, U.S. Attruby revenue reached about $180.6 million, and total second-quarter revenue rose to roughly $243.7 million — a sharp increase from about $110.6 million a year earlier. Analysts broadly expect revenue to roughly double in 2026, with consensus models pointing toward profitability in 2027.

What Could Support a Move Toward the Target

The central bull case rests on Attruby outperforming early expectations. Barclays has argued the launch is tracking ahead of Wall Street's estimates, citing growing prescriber adoption and an expanding addressable market. BridgeBio is not a one-product story: the FDA is reviewing BBP-418 for limb-girdle muscular dystrophy (decision expected in late November 2026) and Encaleret for autosomal dominant hypocalcemia type 1 (decision expected in May 2027). Additional approvals would diversify revenue beyond a single commercial asset.

Favorable analyst revisions, a Strong Buy consensus posture, and improving revenue visibility all support a constructive stock price target environment. If Attruby continues to gain market share and pipeline readouts land favorably, the average analyst price target could drift higher.

What Could Prevent the Target From Being Reached

The company remains unprofitable, with trailing twelve-month EPS (earnings per share) near negative $3.56 and a GAAP net loss of roughly $152 million in the most recent quarter. Any slowdown in Attruby prescriptions, reimbursement friction, or competitive pressure in the ATTR-CM market would weigh on sentiment and valuation. Regulatory setbacks on BBP-418 or Encaleret would remove meaningful optionality.

Valuation is also a consideration: at roughly 13 times trailing revenue and with no positive P/E (price-to-earnings) ratio to anchor the stock, the shares depend heavily on continued growth execution. The wide target range — from $91 to $156 — shows that more cautious analysts already see limited near-term upside.

Technical Levels and Market Structure

BBIO is trading well below its 52-week high of $93.42 set in mid-2026 and above its 52-week low near $52.75. The $93–$94 area stands out as a major resistance level that the stock would need to clear before the $110 target becomes technically relevant. Support has historically emerged near the low-to-mid $50s. The stock is down about 16% over the past three months and roughly 11% year-to-date, despite a roughly 21% gain over the trailing year — a consolidation pattern following a strong rally.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary. Investors should watch the upcoming third-quarter earnings report (estimated around late October 2026) for Attruby sales and any guidance update, the BBP-418 FDA decision expected in late November 2026, and the Encaleret decision in May 2027. Analyst revisions around these milestones, along with broader biotech sector sentiment and interest-rate expectations, will shape the stock's near-term direction.

AI Daily Buy/Sell Signals

For traders tracking names like BBIO, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening. Explore AI Daily Buy/Sell Signals to see how automated analysis can support your decision-making.

Final Assessment

Whether BBIO can reach $110 depends less on a single event than on sustained commercial execution. The $110 central target — the average of verified analyst targets ranging from $91 to $156 — implies a roughly 63% advance from current levels, a very large move that would require the stock to eclipse its 52-week high and re-rate on growth. The bull case is anchored in Attruby's rapid launch and two upcoming FDA decisions; the bear case centers on persistent losses, a premium revenue multiple, and the risk that adoption or regulatory milestones disappoint. With analysts split between cautious Hold-style targets near $91 and aggressive Buy targets above $120, investors should focus on quarterly sales trends and pipeline decisions rather than any single price forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations